Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov .
Updates regarding government operating status and resumption of normal operations can be found at OPM.gov .

Dr. Laura Asnaghi

Dr. Laura Asnaghi

Scientific Review Officer



Biography

Division:
Division of Translational and Clinical Sciences DTCS
Review Branch:
Cancer Diagnosis, Prevention & Therapeutics CDPT
Study Section:
Clinical Oncology CONC

Dr. Laura Asnaghi received her Ph.D. in Biochemistry and Clinical Chemistry from the University of Milan in Italy. She subsequently worked as a postdoctoral fellow in the Laboratory of Cellular Oncology at the National Cancer Institute, before joining the Department of Pathology of Johns Hopkins University, where she was a research faculty in the area of ocular oncology. Her main research efforts were focused on understanding the molecular drivers and signaling pathways associated with tumor progression and invasion in retinoblastoma, uveal (ocular) melanoma and conjunctival squamous cell carcinoma. She demonstrated a critical role for Notch and hypoxia in promoting progression and regulating response to treatment in uveal melanoma and retinoblastoma. She also found that Nodal/TGF-β pathway is highly active in invasive retinoblastomas and inhibition of this signaling potently reduced invasion and proliferation in this pediatric intraocular tumor.

 

Last updated: 07/11/2025 13:16